Abstract
Reduced platelet aggregation by acetylsalicylic acid administration has been associated with adverse outcomes in patients with thrombotic diseases, thus it is important to determine aspirin resistance in those cases. The antiplatelet effect of acetylsalicylic acid is rarely measured, but it has many problems. The aim of this study was to find the evaluation method for antiplatelet effect after administration of acetylsalicylic acid. We developed a particle counting method based upon laser light scattering, and utilized the platelet aggregation agonists, collagen, at 0.25, 0.5 and 1.0 μg/mL, and adenosine diphosphate (ADP), at 0.5, 1.0 and 2.0 μM, to determine their effective concentrations. Seventeen healthy volunteers were administered acetylsalicylic acid at 162 mg/day, with platelet aggregation determined before and 20 min after administration. In all subjects, the rate of platelet aggregation induced by 1.0 μg/mL of collagen before taking acetylsalicylic acid was the highest value obtained, while 20 min after acetylsalicylic acid administration, aggregation induced by collagen at 1.0 μg/mL was significantly decreased as compared to before administration. As for the other concentrations of collagen and all those of ADP tested, platelet aggregation was either not significantly induced before taking acetylsalicylic acid or the rate of aggregation was not significantly decreased after taking acetylsalicylic acid. Our results indicate that collagen at 1.0 μg/mL is appropriate as a platelet aggregation agonist for evaluating the antiplatelet effect of acetylsalicylic acid. Thus, it is useful that the measurement is performed only once.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Awtry EH, Loscalzo J (2000) Aspirin. Circulation 101(10):1206–1218
Benedek IH, Joshi AS, Pieniaszek HJ, King SY, Kornhauser DM (1995) Variability in the pharmacokinetics and pharmacodynamics of low dose aspirin in healthy male volunteers. J Clin Pharmacol 35(12):1181–1186
Berrouschot J, Schwetlick B, von Twickel G, Fischer C, Uhlemann H, Siegemund T, Siegemund A, Roessler A (2006) Aspirin resistance in secondary stroke prevention. Acta Neurol Scand 113(1):31–35. doi:10.1111/j.1600-0404.2005.00419.x
Dai Y, Ge J (2012) Clinical use of aspirin in treatment and prevention of cardiovascular disease. Thrombosis 2012:245037. doi:10.1155/2012/245037
Grundmann K, Jaschonek K, Kleine B, Dichgans J, Topka H (2003) Aspirin non-responder status in patients with recurrent cerebral ischemic attacks. J Neurol 250(1):63–66. doi:10.1007/s00415-003-0954-y
Helgason CM, Bolin KM, Hoff JA, Winkler SR, Mangat A, Tortorice KL, Brace LD (1994) Development of aspirin resistance in persons with previous ischemic stroke. Stroke: J Cereb Circ 25(12):2331–2336
Hideyuki G, Tomohiro S, Hiromi O, Sadami K, Hisashi I (2001) Basic examination using a PA200 for platelet aggregation test. J Clin Lab Instrum Reag 24(4):281–285
Husted SE, Kraemmer Nielsen H, Krusell LR, Faergeman O (1989) Acetylsalicylic acid 100 mg and 1000 mg daily in acute myocardial infarction suspects: a placebo-controlled trial. J Intern Med 226(5):303–310
Kaneo S, Yukio O (2004) Platelet aggregation test. Thromb Circ 12(4):345–348
Kawasaki T, Ozeki Y, Igawa T, Kambayashi J (2000) Increased platelet sensitivity to collagen in individuals resistant to low-dose aspirin. Stroke: J Cereb Circ 31(3):591–595
Komiya T, Kudo M, Urabe T, Mizuno Y (1994) Compliance with antiplatelet therapy in patients with ischemic cerebrovascular disease. Assessment by platelet aggregation testing. Stroke: J Cereb Circ 25(12):2337–2342
Lewis HD Jr, Davis JW, Archibald DG, Steinke WE, Smitherman TC, Doherty JE 3rd, Schnaper HW, LeWinter MM, Linares E, Pouget JM, Sabharwal SC, Chesler E, DeMots H (1983) Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. New Engl J Med 309(7):396–403. doi:10.1056/NEJM198308183090703
Loll PJ, Picot D, Garavito RM (1995) The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase. Nat Struct Biol 2(8):637–643
Lorenz RL, Schacky CV, Weber M, Meister W, Kotzur J, Reichardt B, Theisen K, Weber PC (1984) Improved aortocoronary bypass patency by low-dose aspirin (100 mg daily). Effects on platelet aggregation and thromboxane formation. Lancet 1(8389):1261–1264
Ohmori T, Yatomi Y, Nonaka T, Kobayashi Y, Madoiwa S, Mimuro J, Ozaki Y, Sakata Y (2006) Aspirin resistance detected with aggregometry cannot be explained by cyclooxygenase activity: involvement of other signaling pathway(s) in cardiovascular events of aspirin-treated patients. J Thromb Haemos: JTH 4(6):1271–1278. doi:10.1111/j.1538-7836.2006.01958.x
Picot D, Loll PJ, Garavito RM (1994) The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1. Nature 367(6460):243–249. doi:10.1038/367243a0
Ridker PM, Manson JE, Buring JE, Muller JE, Hennekens CH (1990) Circadian variation of acute myocardial infarction and the effect of low-dose aspirin in a randomized trial of physicians. Circulation 82(3):897–902
Vane JR (1971) Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat: New Biol 231(25):232–235
Conflict of interest
The authors declare no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Yokoyama, H., Mastumura, T., Soeda, S. et al. The evaluation method for antiplatelet effect of acetylsalicylic acid. Eur J Drug Metab Pharmacokinet 39, 327–333 (2014). https://doi.org/10.1007/s13318-013-0170-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13318-013-0170-9